Age-related macular degeneration (AMD) is the leading cause of blindness throughout much of the Western world for individuals older than 50 years of age.
1 Vision loss can occur from the advanced stage, which includes choroidal neovascularization (CNV) or geographic atrophy involving the center of macula. Left untreated, the advanced stage can lead to severely impaired central vision, influencing everyday activities.
2 In the United States, approximately 200,000 individuals older than 50 years of age develop the advanced stage of AMD each year in at least one eye.
3 Left untreated, approximately 70% of these cases develop substantial vision loss in the affected eye within 2 years. Furthermore, of those patients who developed advanced AMD in only one eye, approximately half will develop the advanced stage in the other eye within 5 years, resulting in a high risk of developing legal blindness if left untreated.
1
Although there is no definitive cure for AMD, the Age-Related Eye Disease Study (AREDS) has suggested benefits of certain dietary supplements for slowing the progression of the disease from the intermediate stage to the advanced stage.
4 In addition, recent clinical trials of anti–vascular endothelial growth factor (VEGF) for treating CNV can eliminate a substantial proportion of cases that otherwise would progress to the advanced stage.
5 The better the visual acuity at the onset of anti-VEGF therapy, the greater is the chance of avoiding substantial visual acuity impairment or blindness.
2 Thus, it is critical to identify in a timely manner those individuals most at risk for developing advanced AMD, specifically individuals with the intermediate stage of AMD.
The following drusen classification method was adopted by the AREDS Coordinating Centers
6 : large drusen are defined as those that exceed 125 microns in diameter (the average size of a retinal vein at the optic disk margin), small drusen are defined as those with diameters less than 63 microns, and medium-sized drusen are defined as those with diameters in the range between 63 and 125 microns. The intermediate stage of AMD is characterized by the presence of numerous medium-sized drusen, or at least one large druse within 3000 microns of the center of the macula (
Fig. 1). Although a dilated ophthalmoscopic examination at least every 2 years to detect asymptomatic conditions potentially requiring intervention, such as the intermediate stage of AMD, is recommended by the American Academy of Ophthalmology, the presence of drusen often causes no symptoms and therefore no motivation for an individual to seek examination by an ophthalmologist.
Currently, ophthalmoscopy of the retina by trained health care providers or evaluation of fundus photographs by trained graders remains the most effective method to identify the intermediate stage of AMD.
1 However, grading fundus images manually by a grader can be a tedious process, requiring the expertise of an adequately trained health care provider or extensively trained fundus photograph grader to understand the varying patterns recognized by an ophthalmologist.
7 Furthermore, access to an ophthalmology health care provider at least every 2 years to detect the intermediate stage of AMD after 50 years of age can be challenging for many health care environments. Therefore, there is a need for automated visual diagnostic tools that allow the detection of the intermediate stage AMD among a large pool of the at-risk population. As an example of the potential health care burden of this issue, in 2010, in the United States, there were approximately 98 million individuals older than 50 years of age and this number is projected to increase to approximately 109 million by 2015.
8
A substantial body of work has been devoted to the design of automated retinal image analysis (ARIA) algorithms. Although ARIA algorithms for diabetic retinopathy or glaucoma are showing promise,
9 less progress, in the opinion of the authors, has been made in the area of AMD. Some AMD detection methods require user intervention.
10 Recently, researchers have emphasized automated approaches by using adaptive equalization and wavelets
11 ; applying mathematical morphology
12 on angiographic images; using adaptive thresholding
13 ; exploiting probabilistic boosting approaches for the classification of nonhomogeneous drusen textures
14 ; using probabilistic modeling and fuzzy logic
15 ; applying histogram normalization and adaptive segmentation
16 ; exploiting texture discrimination and the intensity topographical profile
17 ; utilizing morphologic reconstruction
18 ; employing a histogram-based segmentation method
19 ; or, finally, using basic feature clustering to find bright lesions.
20 The interested reader is also referred to a recent review
9 of ARIA techniques.
The objective of our study was to develop and assess methods to automatically process fundus images based on a “visual words” approach, in order to reliably detect evidence of AMD as well as accurately categorize its severity. Because the key factor in mitigating the worsening of AMD as it progresses from the intermediate stage to the neovascular form (and potentially, in the future, the geographic atrophic form) is early intervention, the ultimate goal is to implement these algorithms in a public monitoring or screening system that is convenient and easily accessible to the general public. In essence, the system would analyze fundus images of an individual and quickly provide results including a grade of AMD severity and, if necessary, a recommendation to see an ophthalmologist for further evaluation, while avoiding false-positive referrals.
A natural approach for finding and classifying AMD patients consists of automatically finding drusen in fundus images (which is the aim of most of the above-cited studies) and then using this to detect and classify the severity of AMD. This task may be difficult due to variations in patient-specific appearance (variability in pigmentation of the choroid as well as drusen appearance within and across subjects), and it may be challenging to identify stable image features that are characteristic of drusen that can be used to build a robust classifier that will perform reliably over a large data set. Because of this, the current study uses an alternate strategy that focuses on classifying the entire fundus image, as a whole, as opposed to looking only for specific drusen or other lesions.